The company also added two tertiary analysis partners to PacBio Compatible, Geneyx and Golden Helix, to enable customers to leverage PacBio HiFi data for disease research. PacBio also announced ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent 2024 preliminary results and restructuring ...

PacBio built its business on long-read raw sequence data, analysing DNA sequences of 10,000 base pairs or more, which the company says makes it easier to assemble genome data and is more accurate ...

Jan. 29, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leader in high ... methylomic, and epigenomic data in a synchronized analysis to analyze a 9-month-old patient with an unsolved condition ...

PacBio announced its involvement in a ... methylomic, and epigenomic data in a synchronized analysis to analyze a 9-month-old patient with an unsolved condition involving bilateral retinoblastomas ...

Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer ... the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish ...

With PacBio’s innovative multiomic solutions ... "By integrating genomic, transcriptomic, epigenomic, and methylomic data in a single analysis, we were able to pinpoint multiple molecular ...

Pacific Biosciences of California ... PACB upgraded its Revio platform with SpaRC chemistry, increasing data output by 33%, reducing DNA input needs fourfold, and enabling up to 2,500 HiFi ...

With PacBio’s innovative multiomic solutions ... "By integrating genomic, transcriptomic, epigenomic, and methylomic data in a single analysis, we were able to pinpoint multiple molecular disruptions ...

and methylomic data in a single analysis, we were able to pinpoint multiple molecular disruptions contributing to this rare Mendelian condition—findings that would have been impossible with ...